Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015

Published: November 2015
No. of Pages: 237
   

Global Markets Direct’s, ‘Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015’, provides an overview of the Idiopathic Pulmonary Fibrosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Idiopathic Pulmonary Fibrosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Idiopathic Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Idiopathic Pulmonary Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Idiopathic Pulmonary Fibrosis Overview 10
Therapeutics Development 11
Pipeline Products for Idiopathic Pulmonary Fibrosis - Overview 11
Pipeline Products for Idiopathic Pulmonary Fibrosis - Comparative Analysis 12
Idiopathic Pulmonary Fibrosis - Therapeutics under Development by Companies 13
Idiopathic Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes 18
Idiopathic Pulmonary Fibrosis - Pipeline Products Glance 19
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Idiopathic Pulmonary Fibrosis - Products under Development by Companies 22
Idiopathic Pulmonary Fibrosis - Products under Investigation by Universities/Institutes 27
Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development 28
AdAlta Pty Ltd. 28
Aeolus Pharmaceuticals, Inc. 29
Afferent Pharmaceuticals, Inc. 30
AnaMar AB 31
Biogen, Inc. 32
Bioneer Corporation 33
BiOrion Technologies B.V. 34
Bristol-Myers Squibb Company 35
Carolus Therapeutics, Inc. 36
Celgene Corporation 37
Chong Kun Dang Pharmaceutical Corp. 38
Compugen Ltd. 39
F. Hoffmann-La Roche Ltd. 40
FibroGen, Inc. 41
Galapagos NV 42
GenKyoTex S.A. 43
Gilead Sciences, Inc. 44
Global Blood Therapeutics, Inc. 45
HanAll Biopharma Co., Ltd. 46
HEC Pharm Co., Ltd. 47
Histocell S.L. 48
iBio, Inc. 49
ImmuneWorks, LLC 50
Inventiva SAS 51
Isarna Therapeutics GmbH 52
Kadmon Corporation, LLC 53
Kasiak Research Private Limited 54
Kyorin Pharmaceutical Co., Ltd. 55
LTT Bio-Pharma Co., Ltd. 56
MedImmune, LLC 57
Moerae Matrix, Inc. 58
MorphoSys AG 59
MSM Protein Technologies, Inc. 60
Pacific Therapeutics Ltd. 61
Pharmaxis Limited 62
Progenra, Inc. 63
Promedior, Inc. 64
ProMetic Life Sciences Inc. 65
Pulmatrix, Inc. 66
Respira Therapeutics, Inc. 67
Rhizen Pharmaceuticals SA 68
Ribomic Inc. 69
Sanofi 70
Teva Pharmaceutical Industries Limited 71
Yuhan Corporation 72
Idiopathic Pulmonary Fibrosis - Therapeutics Assessment 73
Assessment by Monotherapy Products 73
Assessment by Combination Products 74
Assessment by Target 75
Assessment by Mechanism of Action 78
Assessment by Route of Administration 81
Assessment by Molecule Type 83
Drug Profiles 85
(pentoxifylline + acetylcysteine) - Drug Profile 85
AEOL-10150 - Drug Profile 86
AF-219 - Drug Profile 89
AM-0010 - Drug Profile 91
AMAP-102 - Drug Profile 92
Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis - Drug Profile 94
Antisense RNAi Oligonucleotide for COPD and IPF - Drug Profile 95
Antisense RNAi Oligonucleotides for Idiopathic Pulmonary Fibrosis - Drug Profile 96
BG-00011 - Drug Profile 97
BMS-986020 - Drug Profile 98
BOT-191 - Drug Profile 99
CC-539 - Drug Profile 100
CC-90001 - Drug Profile 101
CGEN-25009 - Drug Profile 102
CKD-942 - Drug Profile 103
CMYJH-01 - Drug Profile 104
CT-2009 - Drug Profile 105
D-9030 - Drug Profile 106
Drug to Inhibit Galectin-3 for Fibrosis - Drug Profile 107
FG-3019 - Drug Profile 108
GBT-1118 - Drug Profile 110
GBT-440 - Drug Profile 111
GKT-831 - Drug Profile 112
GLPG-1690 - Drug Profile 113
HC-016 - Drug Profile 114
HEC-00000585 - Drug Profile 115
HL-156FIB - Drug Profile 116
HR-017 - Drug Profile 117
IBIOCFB-03 - Drug Profile 118
ICG-001 - Drug Profile 120
ISTH-0047 - Drug Profile 121
IVA-337 - Drug Profile 123
IW-001 - Drug Profile 124
KBP-7018 - Drug Profile 125
KD-025 - Drug Profile 126
lebrikizumab - Drug Profile 127
LT-0011 - Drug Profile 129
LTI-03 - Drug Profile 130
MMI-0100 - Drug Profile 131
MOR-107 - Drug Profile 133
MSM-735 - Drug Profile 134
NAS-911 - Drug Profile 135
Neumomir - Drug Profile 137
OLX-201 - Drug Profile 138
P-013 - Drug Profile 139
PBF-1129 - Drug Profile 140
PBI-4050 - Drug Profile 141
PBI-4425 - Drug Profile 143
pirfenidone - Drug Profile 144
PRM-151 - Drug Profile 145
PUR-1500 - Drug Profile 147
PXS-4820 - Drug Profile 148
RBM-005 - Drug Profile 149
RBM-006 - Drug Profile 150
Refacell-IPF - Drug Profile 151
RP-6503 - Drug Profile 152
RT-234 - Drug Profile 153
SAR-156597 - Drug Profile 154
SD-560 - Drug Profile 155
simtuzumab - Drug Profile 156
Small Molecule for Idiopathic Pulmonary Fibrosis - Drug Profile 158
Small Molecule for Idiopathic Pulmonary Fibrosis - Drug Profile 159
Small Molecules for COPD and IPF - Drug Profile 160
Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis - Drug Profile 161
Small Molecules to Inhibit LOXL2 for Oncology and Idiopathic Pulmonary Fibrosis - Drug Profile 162
Small Molecules to Inhibit PTPN13 for Idiopathic Pulmonary Fibrosis - Drug Profile 163
Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis - Drug Profile 164
SPL-334 - Drug Profile 165
Stem Cell Therapy for Idiopathic Lung Fibrosis - Drug Profile 166
Stem Cell Therapy for Idiopathic Pulmonary Fibrosis - Drug Profile 167
Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile 168
TD-139 - Drug Profile 170
tipelukast - Drug Profile 172
tralokinumab - Drug Profile 174
YH-siRNA1 - Drug Profile 176
ZL-2101 - Drug Profile 177
ZL-2102 - Drug Profile 178
Idiopathic Pulmonary Fibrosis - Recent Pipeline Updates 179
Idiopathic Pulmonary Fibrosis - Dormant Projects 219
Idiopathic Pulmonary Fibrosis - Discontinued Products 222
Idiopathic Pulmonary Fibrosis - Product Development Milestones 223
Featured News & Press Releases 223
Appendix 230
Methodology 230
Coverage 230
Secondary Research 230
Primary Research 230
Expert Panel Validation 230
Contact Us 230
Disclaimer 231

List of Tables

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2015 17
Number of Products under Development for Idiopathic Pulmonary Fibrosis - Comparative Analysis, H2 2015 18
Number of Products under Development by Companies, H2 2015 20
Number of Products under Development by Companies, H2 2015 (Contd..1) 21
Number of Products under Development by Companies, H2 2015 (Contd..2) 22
Number of Products under Development by Companies, H2 2015 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2015 24
Comparative Analysis by Clinical Stage Development, H2 2015 25
Comparative Analysis by Early Stage Development, H2 2015 26
Comparative Analysis by Unknown Stage Development, H2 2015 27
Products under Development by Companies, H2 2015 28
Products under Development by Companies, H2 2015 (Contd..1) 29
Products under Development by Companies, H2 2015 (Contd..2) 30
Products under Development by Companies, H2 2015 (Contd..3) 31
Products under Development by Companies, H2 2015 (Contd..4) 32
Products under Investigation by Universities/Institutes, H2 2015 33
Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H2 2015 34
Idiopathic Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2015 35
Idiopathic Pulmonary Fibrosis - Pipeline by Afferent Pharmaceuticals, Inc., H2 2015 36
Idiopathic Pulmonary Fibrosis - Pipeline by AnaMar AB, H2 2015 37
Idiopathic Pulmonary Fibrosis - Pipeline by Biogen, Inc., H2 2015 38
Idiopathic Pulmonary Fibrosis - Pipeline by Bioneer Corporation, H2 2015 39
Idiopathic Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2015 40
Idiopathic Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2015 41
Idiopathic Pulmonary Fibrosis - Pipeline by Carolus Therapeutics, Inc., H2 2015 42
Idiopathic Pulmonary Fibrosis - Pipeline by Celgene Corporation, H2 2015 43
Idiopathic Pulmonary Fibrosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 44
Idiopathic Pulmonary Fibrosis - Pipeline by Compugen Ltd., H2 2015 45
Idiopathic Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 46
Idiopathic Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H2 2015 47
Idiopathic Pulmonary Fibrosis - Pipeline by Galapagos NV, H2 2015 48
Idiopathic Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H2 2015 49
Idiopathic Pulmonary Fibrosis - Pipeline by Gilead Sciences, Inc., H2 2015 50
Idiopathic Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics, Inc., H2 2015 51
Idiopathic Pulmonary Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H2 2015 52
Idiopathic Pulmonary Fibrosis - Pipeline by HEC Pharm Co., Ltd., H2 2015 53
Idiopathic Pulmonary Fibrosis - Pipeline by Histocell S.L., H2 2015 54
Idiopathic Pulmonary Fibrosis - Pipeline by iBio, Inc., H2 2015 55
Idiopathic Pulmonary Fibrosis - Pipeline by ImmuneWorks, LLC, H2 2015 56
Idiopathic Pulmonary Fibrosis - Pipeline by Inventiva SAS, H2 2015 57
Idiopathic Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2015 58
Idiopathic Pulmonary Fibrosis - Pipeline by Kadmon Corporation, LLC, H2 2015 59
Idiopathic Pulmonary Fibrosis - Pipeline by Kasiak Research Private Limited, H2 2015 60
Idiopathic Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015 61
Idiopathic Pulmonary Fibrosis - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2015 62
Idiopathic Pulmonary Fibrosis - Pipeline by MedImmune, LLC, H2 2015 63
Idiopathic Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H2 2015 64
Idiopathic Pulmonary Fibrosis - Pipeline by MorphoSys AG, H2 2015 65
Idiopathic Pulmonary Fibrosis - Pipeline by MSM Protein Technologies, Inc., H2 2015 66
Idiopathic Pulmonary Fibrosis - Pipeline by Pacific Therapeutics Ltd., H2 2015 67
Idiopathic Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H2 2015 68
Idiopathic Pulmonary Fibrosis - Pipeline by Progenra, Inc., H2 2015 69
Idiopathic Pulmonary Fibrosis - Pipeline by Promedior, Inc., H2 2015 70
Idiopathic Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2015 71
Idiopathic Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H2 2015 72
Idiopathic Pulmonary Fibrosis - Pipeline by Respira Therapeutics, Inc., H2 2015 73
Idiopathic Pulmonary Fibrosis - Pipeline by Rhizen Pharmaceuticals SA, H2 2015 74
Idiopathic Pulmonary Fibrosis - Pipeline by Ribomic Inc., H2 2015 75
Idiopathic Pulmonary Fibrosis - Pipeline by Sanofi, H2 2015 76
Idiopathic Pulmonary Fibrosis - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 77
Idiopathic Pulmonary Fibrosis - Pipeline by Yuhan Corporation, H2 2015 78
Assessment by Monotherapy Products, H2 2015 79
Assessment by Combination Products, H2 2015 80
Number of Products by Stage and Target, H2 2015 82
Number of Products by Stage and Mechanism of Action, H2 2015 85
Number of Products by Stage and Route of Administration, H2 2015 88
Number of Products by Stage and Molecule Type, H2 2015 90
Idiopathic Pulmonary Fibrosis Therapeutics - Recent Pipeline Updates, H2 2015 185
Idiopathic Pulmonary Fibrosis - Dormant Projects, H2 2015 225
Idiopathic Pulmonary Fibrosis - Dormant Projects (Contd..1), H2 2015 226
Idiopathic Pulmonary Fibrosis - Dormant Projects (Contd..2), H2 2015 227
Idiopathic Pulmonary Fibrosis - Discontinued Products, H2 2015 228

List of Figures

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2015 17
Number of Products under Development for Idiopathic Pulmonary Fibrosis - Comparative Analysis, H2 2015 18
Number of Products under Development by Companies, H2 2015 19
Number of Products under Investigation by Universities/Institutes, H2 2015 24
Comparative Analysis by Clinical Stage Development, H2 2015 25
Comparative Analysis by Early Stage Products, H2 2015 26
Assessment by Monotherapy Products, H2 2015 79
Number of Products by Top 10 Targets, H2 2015 81
Number of Products by Stage and Top 10 Targets, H2 2015 81
Number of Products by Top 10 Mechanism of Actions, H2 2015 84
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 84
Number of Products by Routes of Administration, H2 2015 87
Number of Products by Stage and Routes of Administration, H2 2015 87
Number of Products by Top 10 Molecule Types, H2 2015 89
Number of Products by Stage and Top 10 Molecule Types, H2 2015 89

Published By: Global Markets Direct
Product Code: Global Markets Direct13704


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we´┐Żll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: